Introduction and Objective: Overweight/obesity (ow/ob) is increasingly prevalent in T1D, but its impact on vascular complications remains unclear. This study aims to investigate endothelial function in lean (lean T1D) and ow/ob subjects with T1D (T1D+ow/ob), compared to healthy controls.Methods: Endothelial dysfunction was evaluated by flow-mediated dilation (FMD) of the brachial artery and advanced glycation end-products (AGE) by AGE reader in 23 T1D+ow/ob and 23 lean T1D, matched 1:1 for sex, age, and disease duration. A control group of healthy volunteers (n=14) was also evaluated.Results: FMD was significantly lower in T1D than in controls (p=0.02). T1D+ow/ob had a further reduced FMD than lean T1D (9.8[4.9-15.1] vs 15.4[7.4-29.0] %; p=0.05), despite similar classic CV risk factors (Table). AGE levels were higher among T1D than among controls (p=0.016), and negatively associated with FMD (β= -0.31; p= 0.027), independently from confounders. However, AGE did not differ between lean and ow/ob people with T1D.Conclusion: Overweight and obesity further exacerbate endothelial function in people with T1D. Given the increasing prevalence of ow/ob in T1D, further studies are warranted to characterize its impact on vascular and other complications.
R. Amendolara: None. R. Risi: None. L. D’Onofrio: None. F. Barbaro: None. F. De Vita: None. A. Carafa: None. D. Luverà: None. R. Buzzetti: Other Relationship; Abbott, Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Boehringer-Ingelheim, AstraZeneca, Novartis Pharmaceuticals Corporation. E. Maddaloni: Speaker’s Bureau; Abbott, AstraZeneca. Advisory Panel; Novo Nordisk, Merck Sharp & Dohme Corp. Speaker’s Bureau; Eli Lilly and Company, Medicat Technologies and Devices (MTD). Other Relationship; Guidotti, Theras. Speaker’s Bureau; Aurora Biopharma.
European Union through Italian Ministry of University and Research, PRIN project (2022NS7PRM); Sapienza University of Rome Grants 2022 (RP1221816784D0A1)
Source link
Leave a Reply